RNA modifications in radiotherapy resistance and radiosensitization: epitranscriptomic regulation of tumor response to radiation
Frontiers in Cell and Developmental Biology · 10.07.2026 · 14
DOI: 10.3389/fcell.2026.1895114 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 10.07.2026. Verfasst von Hongran Qin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Radiation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radiotherapy (RT) remains a major treatment for solid tumors, but durable tumor control is frequently limited by adaptive DNA repair, altered cell-death thresholds, cancer stemness, metabolic plasticity, and immune escape. RNA modifications have recently emerged as rapid post-transcriptional regulators that enable tumor, stromal, and immune cells to remodel these programs after irradiation. This Mini Review emphasizes three major themes. First, N 6 -methyladenosine (m 6 A) is the best-characterized RNA modification in RT response, with METTL3/METTL14, FTO, ALKBH5, YTH-domain readers, and IGF2BP proteins regulating DNA repair, apoptosis, ferroptosis, stemness, metabolism, and immune checkpoints in a highly context-dependent manner. Second, non-m 6 A modifications, including 5-methylcytosine (m 5 C), N 4 -acetylcytidine (ac 4 C), 7-methylguanosine (m 7 G), and A-to-I RNA editing, are increasingly linked to homologous recombination, metabolic adaptation, innate immune sensing, and immune evasion, although their RT-specific evidence remains limited and should be viewed as emerging rather than established. Third, therapeutic targeting of RNA-modifying enzymes may improve radiosensitization only when guided by tumor type, cellular context, RT dose and fractionation schedule, predictive biomarkers, and normal-tissue safety. Accordingly, we organize current evidence around RNA-modification machinery, tumor-intrinsic mechanisms of radioresistance, immune microenvironment remodeling, and barriers to clinical translation. We further highlight the need to move beyond single-axis models toward dynamic, spatial, and clinically validated analyses of RNA modification networks during fractionated RT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Radiation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
- College of Life Science, University of Chinese Academy of Sciences, Beijing, China.
Zitieren
APA
Qin, H., Yang, S., He, J., Zhao, M., Zhao, L., Wang, J., Jiang, X., Xu, X., & Chen, X. (2026). RNA modifications in radiotherapy resistance and radiosensitization: epitranscriptomic regulation of tumor response to radiation. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1895114
Vancouver
Qin H, Yang S, He J, Zhao M, Zhao L, Wang J, et al. RNA modifications in radiotherapy resistance and radiosensitization: epitranscriptomic regulation of tumor response to radiation. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1895114
BibTeX
@article{Qin2026,
author = {Qin, Hongran and Yang, Shuqiang and He, Jiawei and Zhao, Meijia and Zhao, Luqian and Wang, Jingjing and Jiang, Xiulin and Xu, Xin and Chen, Xiaowen},
title = {RNA modifications in radiotherapy resistance and radiosensitization: epitranscriptomic regulation of tumor response to radiation},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1895114}
}
EUVIMED